This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Chimeric Antigen Receptor (CAR) T-cell Program (Eureka)
Juno Therapeutics Inc.
Drug Names(s): B-cell maturation antigen CAR T-Cell, BCMA CAR T-Cell, CAR T-cell Program
Description: Juno, Eueka, and Memorial Sloan Kettering are developing a proprietary chimeric antigen receptor (CAR) cell therapy that targets the B-cell maturation antigen (BCMA) as well s two additional undisclosed targets.
Juno, Eureka, and Memorial Sloan Kettering
In August 2016, Juno Therapeutics announced that it has entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSK) and Eureka Therapeutics for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma. The binding domains were developed under a collaboration agreement between Eureka Therapeutics and MSK.
MSK and Eureka Therapeutics are eligible to receive an undisclosed upfront payment, additional payments upon the achievement of undisclosed clinical, regulatory, and commercial milestones, and royalties on net sales.
Partners: Memorial Sloan-Kettering Cancer Center Eureka Therapeutics, Inc.
Chimeric Antigen Receptor (CAR) T-cell Program (Eureka) News
Additional information available to subscribers only: